Scilex Holding Company Increase (Decrease) in Accounts Payable and Accrued Liabilities
Scilex Holding Company (SCLX) reported Increase (Decrease) in Accounts Payable and Accrued Liabilities of -$4.36 million for the 6-month period ending 2026-06-30, per its 10-Q filed 2026-08-14.
Financial Statements › Cash Flow › Operating Activities
us-gaap:IncreaseDecreaseInAccountsPayableAndAccruedLiabilities · last filed 2026-08-14
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-06-30 was $3.45M.
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2026-03-31 was -$7.80M, a 1028.06% decline year-over-year.
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-12-31 was -$293.00K.
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for the quarter ending 2025-09-30 was $14.29M, a 617.26% increase year-over-year.
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for fiscal 2025 was $14.60M.
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for fiscal 2024 was -$8.17M, a 453.55% decline from fiscal 2023.
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for fiscal 2023 was $2.31M.
- Scilex Holding Company increase (decrease) in accounts payable and accrued liabilities for fiscal 2022 was -$123.00K, a 118.52% decline from fiscal 2021.
| Period end | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 3 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 6 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 9 month as first filed | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month | Increase (Decrease) in Accounts Payable and Accrued Liabilities 12 month as first filed |
|---|---|---|---|---|---|---|---|---|
| 2026-06-30 | $3.45M derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | -$4.36M 10-Q · filed 2026-08-14 | -$4.65M derived: sum of 3 quarters · filed 2026-08-14 | $9.64M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2026-03-31 | -$7.80M 10-Q · filed 2026-05-20 | -$8.10M derived: sum of 2 quarters · filed 2026-05-20 | $6.20M derived: sum of 3 quarters · filed 2026-05-20 | $5.96M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-12-31 | -$293.00K derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | $14.00M derived: sum of 2 quarters · filed 2026-04-10 | $13.76M derived: sum of 3 quarters · filed 2026-08-14 | $14.60M 10-K · filed 2026-04-10 | ||||
| 2025-09-30 | $14.29M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $14.05M derived: sum of 2 quarters · filed 2026-08-14 | $14.89M 10-Q · filed 2025-11-14 | $4.26M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-06-30 | -$242.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2026-08-14 | $599.00K 10-Q · filed 2026-08-14 | -$10.03M derived: sum of 3 quarters · filed 2026-08-14 | -$8.04M derived: sum of 4 quarters · filed 2026-08-14 | ||||
| 2025-03-31 | $841.00K 10-Q · filed 2026-05-20 | -$9.79M derived: sum of 2 quarters · filed 2026-05-20 | -$7.80M derived: sum of 3 quarters · filed 2026-05-20 | -$8.45M derived: sum of 4 quarters · filed 2026-05-20 | ||||
| 2024-12-31 | -$10.63M derived: 10-K 12 month − 10-Q 9 month · filed 2026-04-10 | -$8.64M derived: sum of 2 quarters · filed 2026-04-10 | -$9.29M derived: sum of 3 quarters · filed 2026-04-10 | -$8.17M 10-K · filed 2026-04-10 | ||||
| 2024-09-30 | $1.99M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-11-14 | $1.34M derived: sum of 2 quarters · filed 2025-11-14 | $2.46M 10-Q · filed 2025-11-14 | -$752.00K derived: sum of 4 quarters · filed 2025-11-14 | ||||
| 2024-06-30 | -$650.00K derived: 10-Q 6 month − 10-Q 3 month · filed 2025-08-13 | $470.00K 10-Q · filed 2025-08-13 | -$2.75M derived: sum of 3 quarters · filed 2025-08-13 | $1.25M derived: sum of 4 quarters · filed 2025-08-13 | ||||
| 2024-03-31 | $1.12M 10-Q · filed 2025-05-14 | -$2.10M derived: sum of 2 quarters · filed 2025-05-14 | $1.91M derived: sum of 3 quarters · filed 2025-05-14 | -$113.00K derived: sum of 4 quarters · filed 2025-05-14 | ||||
| 2023-12-31 | -$3.21M derived: 10-K 12 month − 10-Q 9 month · filed 2025-03-31 | $785.00K derived: sum of 2 quarters · filed 2025-03-31 | -$1.23M derived: sum of 3 quarters · filed 2025-03-31 | $2.31M 10-K · filed 2025-03-31 | ||||
| 2023-09-30 | $4.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2025-01-17 | $1.98M derived: sum of 2 quarters · filed 2025-01-17 | $5.53M 10-Q · filed 2025-01-17 | $6.78M derived: sum of 4 quarters · filed 2025-01-17 | ||||
| 2023-06-30 | -$2.02M derived: 10-Q 6 month − 10-Q 3 month · filed 2024-08-13 | $1.52M 10-Q · filed 2024-08-13 | $2.77M derived: sum of 3 quarters · filed 2024-08-13 | $445.00K derived: sum of 4 quarters · filed 2024-08-13 | ||||
| 2023-03-31 | $3.54M 10-Q · filed 2024-05-13 | $4.79M derived: sum of 2 quarters · filed 2024-05-13 | $2.46M derived: sum of 3 quarters · filed 2024-05-13 | $984.00K derived: sum of 4 quarters · filed 2024-05-13 | ||||
| 2022-12-31 | $1.25M derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | -$1.08M derived: sum of 2 quarters · filed 2024-03-12 | -$2.56M derived: sum of 3 quarters · filed 2024-03-12 | -$123.00K 10-K · filed 2024-03-12 | ||||
| 2022-09-30 | -$2.33M derived: 10-Q 9 month − 10-Q 6 month · filed 2023-11-14 | -$3.81M derived: sum of 2 quarters · filed 2023-11-14 | -$1.37M 10-Q · filed 2023-11-14 | $600.59K 10-Q · filed 2022-11-04 | -$752.57K derived: sum of 4 quarters · filed 2024-03-12 | |||
| 2022-06-30 | -$1.48M derived: 10-Q 6 month − 10-Q 3 month · filed 2023-08-11 | $957.00K 10-Q · filed 2023-08-11 | $389.94K 10-Q · filed 2022-08-12 | $1.58M derived: sum of 3 quarters · filed 2024-03-12 | $1.60M derived: sum of 4 quarters · filed 2024-03-12 | |||
| 2022-03-31 | $2.44M 10-Q · filed 2023-05-12 | -$167.70K 10-Q · filed 2022-05-16 | $3.06M derived: sum of 2 quarters · filed 2024-03-12 | $3.08M derived: sum of 3 quarters · filed 2024-03-12 | $3.10M derived: sum of 4 quarters · filed 2024-03-12 | |||
| 2021-12-31 | $620.43K derived: 10-K 12 month − 10-Q 9 month · filed 2024-03-12 | $643.98K derived: sum of 2 quarters · filed 2024-03-12 | $664.00K derived: sum of 3 quarters · filed 2024-03-12 | $664.00K 10-K · filed 2024-03-12 | $208.70K 10-K · filed 2022-02-24 | |||
| 2021-09-30 | $23.54K derived: 10-Q 9 month − 10-Q 6 month · filed 2022-11-04 | $43.57K derived: sum of 2 quarters · filed 2022-11-04 | $43.57K 10-Q · filed 2022-11-04 | |||||
| 2021-06-30 | $20.02K 10-Q/A · filed 2021-08-24 | $20.02K 10-Q · filed 2022-08-12 | ||||||
| 2021-03-31 | $17.21K 10-Q · filed 2022-05-16 | |||||||
| 2020-12-31 | -$1.07M 10-K · filed 2023-03-07 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Metagenomi Therapeutics, Inc. (MGX) | United States | $0.044B | -0.48 |
| LeonaBio, Inc. (LONA) | United States | $0.047B | -0.61 |
| Instil Bio, Inc. (TIL) | United States | $0.048B | -1.73 |
| Tevogen Inc. (TVGN) | United States | $0.049B | |
| aTYR PHARMA INC (ATYR) | United States | $0.033B | -0.98 |
| Quince Therapeutics, Inc. (QNCX) | United States | $0.031B | |
| CEL SCI CORP (CVM) | United States | $0.030B | -0.81 |
| Inmune Bio, Inc. (INMB) | United States | $0.056B | -2.48 |
| ImageneBio, Inc. (IMA) | United States | $0.056B | -1.31 |
| BioAtla, Inc. (BCAB) | United States | $0.058B | -0.21 |